Nexo-P: Redefining Immuno-Oncology Therapy Solutions for Challenging Cancers

Nexokine Therapeutics is at the forefront of a revolutionary evolution in immuno-oncology (IO) therapies, taking on the unyielding challenges of gastrointestinal (GI) cancers, including colorectal, gastric, and pancreatic cancers. These cancers are notorious for their high mortality rates and limited effective treatment options. Our mission is to develop breakthrough treatments that harness the power of the immune system to transform patient outcomes.

Our innovative approach centres on engaging the immune system in a way that has not been done before, offering a novel strategy to combat cancer. At the heart of our technology is our novel payload, Nexo-P, designed to modulate the tumour microenvironment in ways that current IO therapies cannot achieve.

With funding from IUK-Analysis for Innovators scheme, we are collaborating with Astute, a partner renowned for their specialized analytical capabilities and extensive experience in developing immunotherapies. This partnership ensures that we utilize the most advanced tools and techniques available, guaranteeing high-quality, accurate, and reproducible assays essential for validating our groundbreaking therapies.

Nexokine is unwavering in its commitment to overcoming the toughest challenges in cancer treatment. Our project promises to accelerate the development of our therapies, positioning Nexokine as a trailblazer in the biotech sector. With the potential to drive growth and innovation in the UK biotech industry, we are poised to deliver life-changing solutions that will redefine the landscape of cancer treatment.